Medical declaration form for an ioc restricted substance
ABBREVIATED THERAPEUTIC USE EXEMPTION FORM
Please complete all sections in capital letters or typing. Illegible forms will be returned. beta-2 agonists by inhalation glucocorticosteroids by non-systemic routes * * All routes other than orally, rectally, intravenously and intramuscularly. Topical glucocorticosteroid preparations to treat aural/otic, nasal, buccal cavity and ophthalmic ailments are not prohibited and do not require a Therapeutic Use Exemption Note: Despite the granting of a TUE, when the Laboratory has reported a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL this will be considered as an Adverse Analytical Finding unless the athlete proves that the abnormal result was the consequence of the therapeutic use of inhaled salbutamol. NB - TUE FORMS AND ALL REPORTS AND ACCOMPANYING DOCUMENTS MUST BE COMPLETED IN ENGLISH. 1. Athlete Information
Female Male Date of Birth (d/m/y): …………………………………….
Tel.: …………………………………………………………… E-mail : ……………………………………………………………. (with international code)
International or National Sporting Organization: .
2. Medical information
Diagnosis: …………………………………………………………………………………………………………………………………. …………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………….
N.B. Any ATUE may be reviewed at any time, by the ADO and/or WADA STRICTLY CONFIDENTIAL Version 2.0/18 July 2007 Prohibited substance(s): Frequency Date(s) Genericname Treatment Intended duration of treatment:
(Pleasetick appropriate box)
or duration (week/month): ………………………………
3. Medical practitioner’s and athlete’s declaration
I certify that the above-mentioned treatment is medically appropriate and that the use of alternative medications not on the Prohibited List would be unsatisfactory for this condition. Name: ………………………………………………………………………………………………………… Medical Speciality: ………………………………………………………………………………………. Address: ………………………………………………………………………………………………………. Tel.: …………………………. Fax: ………………………………………………. E-mail: …………………………………………………………………………………………………………. Signature of Medical Practitioner:. Date: . I, ……………………………………………………………… certify that the information under 1. is accurate
and that I am requesting approval to use a Substance or Method from the WADA Prohibited
List. I authorize the release of personal medical information to the Anti-Doping Organization (ADO) as well as to WADA staff, to the WADA TUEC (Therapeutic Use Exemption Committee) and to other ADO under the provisions of the Code. I understand that if I ever wish to revoke
the right of these organizations to obtain my health information on my behalf, I must notify my medical practitioner and my ADO in writing of that fact.
Athlete’s signature: . Date: . Parent’s/Guardian’s signature: . Date: . (if the athlete is a minor or has a disability preventing him/her to sign this form, a parent or guardian shall sign together with or on behalf of the athlete) Incomplete Applications will be returned and need to be resubmitted. Please submit the completed form to the South African Institute for Drug-Free Sport for the attention of Pamela Isaacs: Fax - 021 683 7274/ email: [email protected]
B E S T P R A C T I C E Interventii si strategii pentru renuntarea la fumat1 This Best Practice Information Sheet has been derived from a commissioned review undertaken by The Joanna Briggs Institute. This review sought to identify existing systematic reviews on smoking cessation interventions and strategies. Fifteen systematic reviews were identified that met the inclu
localized to DRAO itself are not the source ofthe transient reversals. The 14.5-month aver-age recurrence is similar to the period of theChandler resonance ( 8 ). Nonetheless, thisresonance cannot explain the observed base-line changes or the sawtooth pattern in thetime series. M. Meghan Miller,* Tim Melbourne, Daniel J. Johnson,earthquake that began on 7 February 2002 atFriday Harbor, Was